Spotlight on Radiology
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1
StartActivity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Radiology Presentations
Interstitial Lung Disease Forum 2021: A Look at the Latest Evidence and Future Perspectives—Session 1
StartActivity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC Credit/AANP Credit
Expires: March 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
- Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
- Assess the latest clinical evidence regarding the treatment of patients with ILD.
Activity Description
Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.
Agenda
Introduction
Steven D. Nathan, MD
Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis
and Classification
Lisa H. Lancaster, MD
Long-Term and Real-World Studies in IPF – What Can We
Learn?
Robert J. Kaner, MD
Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD
Activity Chair
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge MOC points in
the American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider's responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com